Eli Lilly, Medtronic in Parkinson’s disease collaboration
The goal of the collaboration is to develop a therapeutic approach for Parkinson’s disease that combines the strengths of Lilly’s biologic, a modified form of glial cell derived
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.